This site is intended only for healthcare professionals resident in India

Search

Menu

Close

Sign InLog Out
Our medicinesTherapy areasExplore ContentExplore content

  

MaterialsVideosLet's connectLet's ConnectPfizer medical information
Novel Therapieshemophilia_logo.pngNovel TherapiesEventshemophilia_logo.pngAboutAboutWhat is Hemophilia?Hemophilia Burden of DiseaseHeritageDiagnosisDiagnosisSigns and SymptomsInvestigationsTreatmentTreatmentTreatment OptionsNovel TherapiesSupport & ResourcesSupport & ResourcesPatient Support ResourcesHemMobile®Patient Support LeafletsEvents

What Is Hemophilia?

Congenital hemophilia is a lifelong condition that requires constant and careful management.1 The most common type of hemophilia is called hemophilia A and a less common type is called hemophilia B – both of which are caused by a deficiency in a particular clotting factor (VIII and IX, respectively).2

   

Prevalence

   

Hemophilia is quite rare; about 1 in 10,000 people are born with it.2

   

  

Causes of Hemophilia

  

Hemophilia is usually inherited. Inherited hemophilia is caused by a genetic mutation that mainly affects males.2,3

The chances of a child inheriting hemophilia depends on their gender and which parent has the mutated gene.2,3

Non-inherited hemophilia is known as 'sporadic hemophilia' and accounts for approximately one-third of all hemophilia cases. Sporadic hemophilia occurs in people with no family history of hemophilia, where the gene mutation occurs spontaneously rather than being inherited.2

  

  

FVIII, factor VIII; FIX, factor IX.

  

References:

Srivastava A, Santagostino E, Dougall A, et al. WFH Guidelines for the management of hemophilia, 3rd edition [published correction appears in Hemophilia. 2021;27(4):699]. Hemophilia. 2020;26(suppl 6):1-158.What is hemophilia? World Federation of Hemophilia. Accessed April 27, 2022. http://www1.wfh.org/publications/files/pdf-1324.pdfHemophilia A. National Organization for Rare Disorders. Accessed April 27, 2022. https://rarediseases.org/rare-diseases/hemophilia-a/Hemophilia B. National Organization for Rare Disorders. Accessed April 27, 2022. https://rarediseases.org/rare-diseases/hemophilia-b/

  

For the use only of Registered Medical Practitioners or a Hospital or a Laboratory.

PP-BEN-IND-0024  22/7/22
About
Support Your Patients

Pfizer is committed to supporting you and your patients with hemophilia.
Learn more about the patient resources available to support your patients.

Patient support resources
  
Diagnosis

Refresh your knowledge about the symptoms and diagnosis of hemophilia and understand why early diagnosis and treatment may be important for your patients.

Signs and symptoms


Treatment

Understand the current treatment options and recommendations for patients with hemophilia A and B.
 

Treatment options
PfizerPro AccountPfizerPro Account

To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.

Sign in or RegisterSign inRegisterAccountSign Out
 
These pages are not intended for patients or for members of the general public. The web pages contain promotional content. For the use only of Registered Medical Practitioners or a Hospital or a Laboratory. Full prescribing information available on request. For more details on, Who is a Registered Medical Practitioner, please visit "https://cdsco.gov.in/opencms/export/sites/CDSCO_WEB/Pdf-documents/acts_rules/2016DrugsandCosmeticsAct1940Rules1945.pdf", Page No. 39, Rule 2 part (ee), last accessed on 26th April2021.
​​​​​​​
Address: The Capital,  A Wing, 1802, 18th Floor, Plot No. C-70, ‘G’ Block, Bandra Kurla Complex, Bandra East, Mumbai – 400051, India.
 
PP-BEN-IND-0024

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.

Heading

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.

ButtonButton

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Hac habitasse platea dictumst quisque sagittis purus sit amet volutpat. Lectus magna fringilla urna porttitor rhoncus. Venenatis urna cursus eget nunc scelerisque viverra. Id donec ultrices tincidunt arcu non sodales.

Sagittis aliquam malesuada bibendum arcu vitae elementum curabitur. Pellentesque elit ullamcorper dignissim cras tincidunt. Orci ac auctor augue mauris augue neque. Dui vivamus arcu felis bibendum ut tristique et egestas quis. Sed vulputate mi sit amet mauris commodo.

Nunc eget lorem dolor sed viverra ipsum. Sed ullamcorper morbi tincidunt ornare.

Copyright © 2023 Pfizer Limited, India. All rights reserved. Applicable for Pfizer Products, Product Microsites and Therapy Areas section of the website:
  • All content published herein is intended and strictly only for informational, educational, academic and/or research purposes and shall not be utilized to diagnose or treat a health problem or disease without referring to the full prescribing information for list of approved indications as contained in the product package insert
  • While due care and caution has been taken to ensure that the content herein is free from mistakes or omissions, Pfizer makes no claims, promises or guarantees about the accuracy, completeness or adequacy of the information herein
For the use only of Registered medical practitioners* or a Hospital or a Laboratory

These pages are not intended for patients or for members of the general public. The web pages contain promotional content.

 

If you select 'No', you will be redirected to Pfizer.co.in

For more details on, Who is a Registered medical practitioner*, please visit https://cdsco.gov.in/opencms/export/sites/CDSCO_WEB/Pdf-documents/acts_rules/2016DrugsandCosmeticsAct1940Rules1945.pdf , Page No. 39, Rule 2 part (ee), last accessed on 26th April 2021.
Address: The Capital, A Wing, 1802, 18th Floor, Plot No. C-70, 'G' Block, Bandra Kurla Complex, Bandra East, Mumbai - 400051.


PP-DOL-IND-0251 18 JAN 2023Yes No
You are now leaving PfizerPro website
​
​​​​​You are now leaving Pfizer Pro website and will be redirected to another website. Note that you will be governed by the Terms & Conditions and Privacy Policy of the external website. Would you like to continue?
PP-DOL-IND-0251 18 JAN 2023